Confidential listing · Roorkee, Uttarakhand · Full sale
The short answer
A running, WHO-GMP certified pharmaceutical formulation company near Roorkee, Haridwar district, Uttarakhand is offered for full sale at an asking price of INR 25 crore. Declared annual turnover is about INR 24 crore.
The plant was commissioned in 2023 on about 7,000 sq m of land with about 3,500 sq m built up. It has two manufacturing blocks for tablets, hard gelatin capsules, oral liquids, external preparations and dry syrups, an in-house QC and microbiology laboratory, and about 150 products on its declared product list. Its Site Master File was revised to the revised Schedule M in December 2025.
- Asking priceINR 25 Cr
- Turnover~INR 24 Cr / yr
- Commissioned2023
- Land / built-up~7,000 / ~3,500 sq m
- CertificationWHO-GMP, ISO 9001:2015
- Workforce121 employees
Source of the figures. Areas, sections, utilities, headcount and certifications come from the seller’s Site Master File (Revision R2, effective December 2025). The price and turnover were supplied by the seller. Laafon Galaxy has not verified any of them; use this page to plan a site visit and document check.
The facility
Photographs supplied by the seller. Select any image to enlarge it.
-
Production corridorEpoxy floor with coved skirting, flush vision-panel doors and return-air risers. -
Secondary corridorFlush doors marked for directional flow, with recessed lighting. -
In-process quarantineDedicated coated tablet and capsule quarantine room; pressure gauges above the doors.
What you are buying
Licences and certifications
- Two State manufacturing licences, both granted in 2023 by the Food Safety and Drug Administration, Uttarakhand (Dehradun) [5]. The licence numbers indicate one general licence and one for Schedule C/C(1) products, which would normally be Form 25 and Form 28. Confirm the form types against the licence copies.
- WHO-GMP and ISO 9001:2015 certification declared. The seller also states the site has been inspected by overseas regulators; the audit list is held in an appendix released after NDA.
- Revised Schedule M: Site Master File revised under change control in December 2025, “updated as per revised Schedule M”.
The SMF says the licences are “valid for 5 years”. Since G.S.R. 1337(E) of 27 October 2017, renewal has been replaced by a licence retention fee payable every five years [4]. Ask for proof that the first retention fee has been paid when it falls due.
Ask at diligence: the product permission list endorsed on each licence, not just the licence copies. That list shows which of the roughly 150 products you can legally make on day one.
Block-wise layout, as declared
| Block | Declared use | Area |
|---|---|---|
| Block B | Ground: tablets, capsules, packing, warehouse. First floor: oral liquids, ointments, creams, gels | 1,860 sq m |
| Block C | Ground: QC laboratory. First floor: microbiology laboratory | 376 sq m |
| Block D | Tablets, capsules, dry powder for oral suspension; packing | 393 sq m |
| Utility block | Water system, compressors, HVAC plant | 450 sq m |
Scroll the table sideways on a phone.
Two blocks means real segregation. Block D provides a second tablet and capsule line, so beta-lactam-free campaigns, a separate dry-syrup line or capacity expansion don’t have to share one floor plate.
Reconcile the areas. The block figures add up to about 3,079 sq m against the declared 3,500 sq m built-up, and Block B’s 1,860 sq m is repeated for every section and floor. Ask for the approved building plan and a room-wise area statement, and check them against the Schedule M area benchmarks.
About 150 declared products, by group
- Neuro-vitamin and nutritional combinations: methylcobalamin, alpha lipoic acid, L-methylfolate, benfotiamine; calcium with vitamin D3; iron and folic acid.
- Pain and inflammation: aceclofenac, diclofenac, etoricoxib and serratiopeptidase combinations; trypsin-bromelain.
- Anti-infectives: azithromycin, levofloxacin, doxycycline, clarithromycin and linezolid (several with lactic acid bacillus); ofloxacin-ornidazole.
- Neuropathic pain: pregabalin and gabapentin with methylcobalamin.
- Dermatologicals: clobetasol, beclomethasone, fusidic acid and clindamycin creams and gels.
- Oral liquids and dry syrups: multivitamin, iron and lycopene syrups; azithromycin oral suspension.
Screen the list before you value it. Most of the portfolio is fixed-dose combinations. Check every product against the current banned-FDC notifications and the licence endorsement, and value only what is both permitted and actually selling.
Utilities and quality control, as declared
- HVAC: 24 air handling units, 10% fresh air, terminal HEPA filtration, a dedicated AHU for each process area, and differential pressure cascades.
- Purified water: RO, mixed bed and UV train rated at 1,000 L/h. Separate SS 316L storage and loop for Block B and Block D, online TOC and conductivity, weekly hot-water sanitisation at 80°C, and zero-dead-leg user points.
- Effluent: an on-site ETP, with treated water discharged to the drain and sludge sent for incineration.
- Compressed air: 80 CFM compressor, 0.2 µ filtration at user points, tested to ISO 8573.
- QC: chemical, instrumental and microbiology sections, HPLC method development, stability studies and environmental monitoring.
Three things to raise early:
- No boiler or steam source is described. Confirm how oral liquids and ointments are heated.
- No Pollution Control Board consent is mentioned. Ask for the current consent to operate (air and water) and its expiry date.
- Documentation is manual. A revised Schedule M inspector will look hard at data integrity in the QC lab, so ask about the HPLC audit trail and backups.
Is INR 25 crore a fair ask?
The asking price is about 1.04 times declared turnover. Turnover alone doesn’t set value; earnings do. Enter your own margin and multiple assumptions below.
Implied value: INR 23.0 Cr
About INR 2.0 Cr below the INR 25 Cr ask.
Illustrative only. The slider defaults are placeholders, not the seller’s numbers. Base your offer on audited accounts and on the value of the land and building, which usually sets the floor price.
To compare against the cost of building from scratch, use the plant setup cost calculator.
Revised Schedule M and the licences
The revised Schedule M was notified as G.S.R. 922(E) on 28 December 2023 [1]. Firms with turnover up to INR 250 crore, which includes this one, had until 31 December 2025 [2]. State inspections against the new standard have been under way since November 2025 [3]. A 2023 building with an SMF already revised to the new standard starts from a strong position. Ask for the gap assessment and the latest State inspection report to confirm it.
| Deal structure | What happens to the licences |
|---|---|
| Share purchase | The licensee company stays the same and the licences continue. Notify the Licensing Authority of the change in constitution; the licence then stays valid for up to three months unless a fresh licence is taken [6]. You inherit the company’s history, including past liabilities. |
| Asset purchase | The licences stay with the seller. You need a fresh application, inspection and grant against the revised Schedule M, and production stops until they are granted. |
Scroll the table sideways on a phone.
Eight questions to put to this seller
- Licence copies, the endorsed product permission lists, and the form type of each licence.
- The WHO-GMP certificate with its validity, and the list of overseas regulatory audits.
- Three years of audited accounts, split between own-brand sales and third-party manufacturing.
- The machine-wise equipment list, and achieved output per shift worked out from batch records.
- The revised Schedule M gap assessment and the latest FSDA Uttarakhand inspection report.
- A banned-FDC screen of the 150-product list, with the top 20 products by revenue.
- The Pollution Control Board consent to operate, ETP capacity, and how steam and heating are supplied.
- Share or asset sale, and which approved technical staff will stay on.
For everything else, use our 50-point pharma plant acquisition checklist.
Deal terms and ideal buyer
This is a full sale of the running company with its land, building, machinery, utilities, licences, product permissions and documentation, at INR 25 crore. Financials, licence copies and technical files are shared only after a mutual NDA.
Who it suits: a marketing or PCD company that wants to stop relying on third-party manufacturers; a group adding North India capacity with a WHO-GMP export base; or a CDMO that wants two segregated oral solid lines with liquids and topicals under one licence.
Register interest in this Roorkee unit
In your first message, send your company name, business model and how you plan to use the plant. Put WHO-GMP Pharma Company for Sale in Roorkee in the subject line.
Darshan Singh · Promoter representative
Email: contact@laafon.com
Phone / WhatsApp: 9812446733
Frequently asked questions
The asking price is INR 25 crore for a full sale of the running company. Declared annual turnover is about INR 24 crore. Audited financials are shared after a mutual NDA.
Tablets, hard gelatin capsules, oral liquids, external preparations (ointments, creams and gels) and dry powder for oral suspension, across two manufacturing blocks. About 150 products appear on the declared product list.
The seller declares WHO-GMP and ISO 9001:2015 certification. The Site Master File was revised to the revised Schedule M in December 2025. Confirm both with the certificate, the gap assessment and the latest State inspection report.
In a share purchase, the licensee company stays the same and the licences continue once the Licensing Authority has been told of the change in constitution. In an asset purchase they do not transfer; you need fresh licences from the Food Safety and Drug Administration, Uttarakhand.
About 7,000 sq m of land and about 3,500 sq m built up. The plant was commissioned for commercial production in 2023 and has 121 employees.
Enquiries get the level of detail shown on this page. Licence copies, financials and technical files are released through a data room after a mutual NDA, and then a site visit is arranged. Bring a quality professional to the visit.
References
- Ministry of Health and Family Welfare. Drugs (Amendment) Rules, 2023 (revised Schedule M). G.S.R. 922(E), 28 December 2023. Notified text (PDF). Accessed September 2026.
- Ministry of Health and Family Welfare. Revised Schedule M deadline extended to 31 December 2025 for manufacturers with turnover up to INR 250 crore. G.S.R. 127(E), 11 February 2025. Reported by CliniExperts. Secondary source.
- Business Standard. Pharma units likely to face action for Schedule M violations: experts. 8 November 2025. business-standard.com. Trade press.
- Ministry of Health and Family Welfare. Drugs and Cosmetics (Tenth Amendment) Rules, 2017. G.S.R. 1337(E), 27 October 2017 (licence renewal replaced by a retention fee every five years). Summary on Mondaq. Accessed September 2026.
- Food Safety and Drug Administration, Uttarakhand. Official portal. fda.uk.gov.in. Accessed September 2026.
- Drugs and Cosmetics Rules, 1945. Form 25 (Rule 70) and Form 28 (Rule 76): licence conditions on change in the constitution of the firm. Specimen licence text (PDF). Accessed September 2026.
This listing is commercial and technical information for prospective buyers. It is not investment, legal or tax advice, and it is not an offer. All figures are declared by the seller and have not been independently verified by Laafon Galaxy Pharmaceuticals. Check them against original documents and a physical inspection, and confirm the current regulatory position with the Food Safety and Drug Administration, Uttarakhand and your own advisers before committing funds.
